The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Lysophosphatidic Acid as a Potential Biomarker for Ovarian and Other Gynecologic Cancers
Abstract
CONTEXT: Lysophosphatidic acid (LPA) has been shown to stimulate proliferation of ovarian cancer cells and is present in the ascitic fluid of patients with ovarian cancer. OBJECTIVES: To determine whether elevated levels of LPA are present in plasma from patients with ovarian cancer and other gynecologic malignancies compared with healthy controls and to evaluate whether an elevated LPA plasma level may be a biomarker for these diseases. DESIGN: A research assay was used to measure total LPA levels in plasma from healthy women and women with different diseases. All LPA assays and comparison of LPA levels and CA125 (an ovarian cancer biomarker) levels were performed by observers blinded to patient status or group. SETTING: The Cleveland Clinic Foundation. PARTICIPANTS: A convenience sample of 48 healthy control women, 48 women with ovarian cancer, 36 women with other gynecologic cancers, 17 women with benign gynecologic diseases, 11 women with breast cancer, and 5 women with leukemias. MAIN OUTCOME MEASURES: Total LPA levels in plasma samples from patients and controls. RESULTS: Patients in the ovarian cancer group had significantly higher plasma LPA levels (mean, 8.6 micromol/L; range, 1.0-43.1 micromol/L) compared with the healthy control group (mean, 0.6 micromol/L; range, <0.1-6.3 micromol/L) (P<.001). Elevated plasma LPA levels were detected in 9 of 10 patients with stage I ovarian cancer, 24 of 24 patients with stage II, III, and IV ovarian cancer, and 14 of 14 patients with recurrent ovarian cancer. Of 36 patients with other gynecologic cancers, 33 also showed higher LPA levels(mean, 14.9 micromol/L; range, <0.1-63.2 pmol/L), compared with healthy controls (P<.001). Elevated plasma LPA levels were detected in 5 of 48 controls and 4 of 17 patients with benign gynecologic diseases and in no women with breast cancer or leukemia. In comparison, among a subset of patients with ovarian cancer, 28 of 47 had elevated CA125 levels, including 2 of 9 patients with stage I disease. CONCLUSIONS: Plasma LPA levels may represent a potential biomarker for ovarian cancer and other gynecologic cancers. However, these findings are preliminary and require confirmation in larger studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Methods for Rates and Proportions
Fleiss, J. L., Levin, B., & Paik, M. C. (2003) · Wiley Series in Probability and Statistics · doi:10.1002/0471445428 · Cited by 18,646
Statistical Methods for Rates and Proportions.
Everitt, B. S., & Fleiss, J. L. (1981) · Biometrics · doi:10.2307/2530193 · Cited by 8,990
Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine
Zweig, M. H., & Campbell, G. (1993) · Clinical Chemistry · doi:10.1093/clinchem/39.4.561 · Cited by 6,569
Statistical Methods for Rates and Proportions, 2nd ed
GROVE, W. A. (1981) · American Journal of Psychiatry · doi:10.1176/ajp.138.12.1644-a · Cited by 3,748
Nonparametrics: Statistical Methods Based on Ranks
Mergenthaler, M. J., & Lehmann, E. L. (1979) · Technometrics · doi:10.2307/1268531 · Cited by 3,329
WHO Handbook for Reporting Results of Cancer Treatment
Palmer, M. K. (1982) · British Journal of Cancer · doi:10.1038/bjc.1982.83 · Cited by 2,198
A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer
Bast, R. C., Klug, T. L., John, E. S., Jenison, E., Niloff, J. M., Lazarus, H., Berkowitz, R. S., Leavitt, T., Griffiths, C. T., Parker, L., et al. (1983) · New England Journal of Medicine · doi:10.1056/nejm198310133091503 · Cited by 2,135
Nonparametrics: Statistical Methods Based on Ranks.
Beaver, R. J., & Lehmann, E. L. (1976) · Biometrics · doi:10.2307/2529529 · Cited by 2,047
WHO handbook for reporting results of cancer treatment
Sylvester, R. (1980) · Controlled Clinical Trials · doi:10.1016/0197-2456(80)90009-4 · Cited by 1,055
The bioactive phospholipid lysophosphatidic acid is released from activated platelets
Eichholtz, T., Jalink, K., Fahrenfort, I., & Moolenaar, W. H. (1993) · Biochemical Journal · doi:10.1042/bj2910677 · Cited by 645
Lysophosphatidic Acid, a Multifunctional Phospholipid Messenger
Moolenaar, W. H. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12949 · Cited by 584
Tigyi, G., & Miledi, R. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36618-9 · Cited by 346
Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients.
Xu, Y., Gaudette, D. C., Boynton, J., Frankel, A., Fang, X. J., Sharma, A., Hurteau, J. A., Casey, G., Goodbody, A., & Mellors, A. (1995) · PubMed · Cited by 322
Self-citationLysophospholipids activate ovarian and breast cancer cells
Xu, Y., Fang, X. J., Casey, G., & Mills, G. B. (1995) · Biochemical Journal · doi:10.1042/bj3090933 · Cited by 282
Self-citationLysophosphatidic acids induce proliferation of cultured vascular smooth muscle cells from rat aorta
Tokumura, A., Iimori, M., Nishioka, Y., Kitahara, M., Sakashita, M., & Tanaka, S. (1994) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1994.267.1.c204 · Cited by 192
Gerrard, J. M., & Robinson, P. (1989) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(89)90112-4 · Cited by 181
LPA: a novel lipid mediator with diverse biological actions
Moolenaar, W. H. (1994) · Trends in Cell Biology · doi:10.1016/0962-8924(94)90144-9 · Cited by 153
Mills, G. B., May, C., Hill, M., Campbell, S., Shaw, P. H., & Marks, A. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114784 · Cited by 141
Watson, S. P., McConnell, R. T., & Lapetina, E. G. (1985) · Biochemical Journal · doi:10.1042/bj2320061 · Cited by 76
Early ovarian cancer: A review of its genetic and biologic factors, detection, and treatment
Boente, M. P., Hamilton, T. C., Godwin, A. K., Buetow, K. H., Kohler, M. F., Hogan, W. M., Berchuck, A., & Young, R. C. (1996) · Current Problems in Cancer · doi:10.1016/s0147-0272(96)80005-5 · Cited by 12
Activation of human ovarian cancer cells: role of lipid factors in ascitic fluid
Xu, Y., & Mills, G. B. (1995) · Springer eBooks · doi:10.1007/978-1-4757-0136-4_13 · Cited by 8
Self-citationMills, G., Rosen, B. P., Osborne, R., Bryson, P., & DePetrillo, A. D. (1990) · Gynecologic Oncology · doi:10.1016/0090-8258(90)90216-8 · Cited by 5
Cited by
Sturgeon, C. M., Duffy, M. J., Stenman, U.-H., Lilja, H., Brünner, N., Chan, D. W., Babaian, R., Bast, R. C., Dowell, B., Esteva, F. J., et al. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.105601 · Cited by 1,129
The emerging role of lysophosphatidic acid in cancer
Mills, G. B., & Moolenaar, W. H. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1143 · Cited by 1,094
Ovarian Surface Epithelium: Biology, Endocrinology, and Pathology*
Auersperg, N., Wong, A. S. T., Choi, K.-C., Kang, S. K., & Leung, P. C. K. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.2.0422 · Cited by 1,046
LPA Receptors: Subtypes and Biological Actions
Choi, J. W., Herr, D. R., Noguchi, K., Yung, Y. C., Lee, C.-W., Mutoh, T., Lin, M.-E., Teo, S. T., Park, K. E., Mosley, A. N., et al. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105753 · Cited by 839
Lysophospholipid Receptors: Signaling and Biology
Ishii, I., Fukushima, N., Ye, X., & Chun, J. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073731 · Cited by 771
Metadata
- Authors
- Xu, Y.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 1998-08-26
- Volume
- 280
- Issue
- 8
- Pages
- 719
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2028038006
- Cited by
- 637
- References
- 22
- FWCI
- 22.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.